NCT06582732 - Performance of the Travoprost Intraocular Implant | Biotech Hunter

Enrollment

210

Participants

Timeline

Start Date

March 10, 2021

Primary Completion Date

November 2, 2023

Study Completion Date

November 2, 2023

Conditions

Glaucoma, Open-AngleOcular Hypertension

Interventions

DRUG

Travoprost Intracameral Implant exchanged at Month 12

intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 12

DRUG

Travoprost Intracameral Implant exchanged at Month 3

intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 3

DRUG

Travoprost Intracameral Implant exchanged at Month 6

intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 6

DRUG

Travoprost Intracameral Implant exchanged at Month 24

intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 24

DRUG

Travoprost intracameral implant exchanged at Month 21

intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 21

DRUG

Travoprost intracameral implant exchanged at Month 18

intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 18

DRUG

Travoprost intracameral implant exchanged at Month 15

intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 15

Trial Locations (1)

Glaukos Clinical Study Site, Yerevan